Adrian Newman-Tancredi, PhD, DSc
Chief Scientific Officer at Neurolixis
Location: Dana Point, California, United States
Adrian Newman-Tancredi, PhD, DSc, has over 20 years' experience of neuroscience research and drug discovery. Prior to joining Neurolixis as chief scientific officer, he was director of neurobiology at Pierre Fabre, where he led multi-disciplinary programs that successfully identified novel CNS drugs. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology team at Servier, where he investigated signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella), piribedil (Trivastal), agomelatine (Valdoxan), levomilnacipran (Fetzima) and befiradol (NLX-112). In addition, Dr. Newman-Tancredi managed projects that led to early development of the innovative serotonergic "biased agonist", F15599 (NLX-101).
Dr. Newman-Tancredi has published over 140 research reports, co-authored patents on NCEs and given presentations to a wide variety of audiences. He received his BSc with honors in biochemistry, followed by a PhD and a DSc in neuropharmacology, from the University of Kent at Canterbury, United Kingdom.
- Predicting the Efficacious Dose of the Selective 5-HT1A Agonist NLX-112 (2014)
- Anti-dyskinetic Activity of the Selective 5-HT1A Agonist NLX-112: Behavioral and Microdialysis Studies (2014)
- Preferential Targeting of Subpopulations of 5-HT1A Receptors: Microdialysis Study (2013)
- Preferential Targeting of Subpopulations of 5-HT1A Receptors (2011)